CS INSIGHTS BIOTECH MARKET / BUSINESS INTELLIGENCE Sotio 22/8/2021 June 2021 Review of news from the most innovative therapeutic areas and the business development transactions by Jakub Jarolím, Business Intelligence Department MARKET Multiple companies announced updated results during ASCO meeting The ASCO annual meeting took place virtually beginning of June, where multiple companies presented their updated results of ongoing trials. This led to share price changes and therefore to NBI increased beginning of June by 6% and remains now consistent. NEWS DETAIL ANTIBODY-DRUG CONJUGATES ADC Therapeutics presented updated clinical data on its Zynlonta and Cami Remegen Ltd.’s HER2-targeted disitamab vedotin became the first domestic ADC to win marketing approval in China, just three months after the company scored its first NDA approval in China for its lupus drug Tai’ai (telitacicept). NEWS DETAIL INTERLEUKIN-15 AND INTERLEUKIN-2 Alkermes announced durable and deepening responses of its nemvaleukin in Phase 1/2 Alkermes announced new data from its ARTISTRY clinical development program for nemvaleukin alfa, the investigational engineered IL-2 variant immunotherapy. The data are being presented at ASCO. NEWS DETAIL CELL THERAPIES China granted first CAR T approval to Fosun-Kite’s Yescarta China’s drug regulator granted a first CAR T therapy approval to Fosun Kite Biotechnology’s FKC-876. Marketed as Yescarta (axicabtagene ciloleucel) in the US and EU, the approval by the National Medical Production Administration for the CD19-directed CAR T therapy came 3.5 years after the FDA nod. NEWS DETAIL OTHER INNOVATIVE TREATMENT AREAS Daiichi Sankyo wins approval in Japan for first-ever oncolytic virus therapy treating malignant glioma Daiichi Sankyo has received conditional approval from Japan’s Ministry of Health, Labour and Welfare for its oncolytic virus Delytact (teserpaturev/G-47delta) to treat malignant glioma. The approval marks the first-ever oncolytic virus therapy option to patients with glioblastoma and other malignant gliomas that are not controlled with currently available treatments. The therapy is Daiichi Sankyo’s fourth cancer medicine approved in Japan over the past two years. NEWS DETAIL ONCOLOGY TRANSACTIONS BMS pays $650 million upfront for anti-FOLR1 ADC from Eisai, plus $2.5 billion in milestones PARTNERING In the latest example of ADC attracting high-value deals, BMS is adding anti-FOLR1 ADC MORAb-202 to its pipeline through a $650 million collaboration with Eisai. The new deal supports BMS’s early pipeline strategy focused on broad mechanistic diversity. NEWS DETAIL DISCLAIMER / SOTIO Legal notice NEWS DETAIL Share on social networks NEWS TO EMAIL Get the latest press releases, interviews, podcasts, and insights. SUBSCRIBE TO NEWS FOLLOW US FOR MEDIA For Media Press Releases Interviews and Podcasts Subscribe To News Downloads Contacts MAY BE OF INTEREST Our Companies Newsroom Insights CONTACTS PPF Group Companies TERMS OF USE DATA PROTECTION SITEMAP COOKIES POLICY COOKIES SETTINGS 2021 © PPF GROUP Cookies Consent We are using cookies for the best experience on our websites. For more information visit our document Information about cookies on the "Cookies settings" menu. By clicking accept all cookies you agree with our use of all the types of cookies. If you want to alter the types of cookies, you can do this in our "Cookies settings" menu. By clicking "Deny cookies" you are refusing all cookies, except cookies necessary for website functionality. Information about cookies Cookies Settings Deny Cookies Accept All Cookies